Chemoimmunotherapy Continues to Display Survival Benefits in Small Cell Lung Cancer
Atezolizumab (Tecentriq), durvalumab (Imfinzi), pembrolizumab (Keytruda), and nivolumab (Opdivo) have demonstrated improved survival in combination with etoposide and platinum (EP) in untreated extensive-stage small cell lung cancer (ES-SCLC), cementing checkpoint inhibition plus chemotherapy as a frontline standard, explained Yanyan Lou, MD, PhD.
IMpower133 was the first phase 3 trial to test the addition of a checkpoint inhibitor to chemotherapy in the first-line setting in ES-SCLC. Patients with untreated ES-SCLC were randomized to atezolizumab plus EP for 4 cycles followed by maintenance atezolizumab or placebo plus EP for 4 cycles followed by placebo maintenance. Read more.